Results 21 to 30 of about 3,696 (214)
Mechanisms for Tuning Engineered Nanomaterials to Enhance Radiation Therapy of Cancer
Advanced Science, Volume 7, Issue 24, December 16, 2020., 2020 Engineered nanomaterials that produce reactive oxygen species on exposure to X‐ and gamma‐rays used in radiation therapy offer promise of novel cancer treatment strategies including in deep tissue. This review focuses on mechanisms underpinning rational nanomaterial design to enhance radiation therapy, the understanding of which will enable novel ways ...
Sandhya Clement +7 more
wiley +1 more source
Radiation Oncology, 2018 Background To assess the effect of radiochemotherapy (RCT) on proposed tumour hypoxia marker transverse relaxation time (T2*) and to analyse the relation between T2* and 18F-misonidazole PET/CT (FMISO-PET) and 18F-fluorodeoxyglucose PET/CT (FDG-PET ...
Nicole Wiedenmann +16 more
doaj +1 more source
In vitro metabolism of misonidazole [PDF]
British Journal of Cancer, 1981 Misonidazole (MISO) is a nitroimidazole drug currently undergoing clinical trials as a radiosensitizer of hypoxic tumour cells. The drug is also toxic to such cells, probably because of metabolic activation of the nitro group under hypoxia. The metabolic fate of 14C-labelled MISO is examined, using hypoxic mammalian (CHO) cells in vitro.
P D, Josephy, B, Palcic, L D, Skarsgard
openaire +2 more sources
Absence of a dose-rate effect in the transformation of C3H 10T1/2 cells by α-particles [PDF]
, 1987 The findings of Hill et al. (1984) on the greatly enhanced transformation frequencies at very low dose rates of fission neutrons induced us to perform an analogous study with -particles at comparable dose rates. Transformation frequencies were determined
Balcer-Kubiczek E.K. +20 more
core +1 more source
RRx-001, A novel dinitroazetidine radiosensitizer. [PDF]
, 2016 The 'holy grail' in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer-a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant ...
Bednarski, Mark +7 more
core +1 more source
Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy. [PDF]
, 2016 Tumor hypoxia, a common feature occurring in nearly all human solid tumors is a major contributing factor for failures of anticancer therapies. Because ionizing radiation depends heavily on the presence of molecular oxygen to produce cytotoxic effect ...
Beom Ju Hong +5 more
core +1 more source
, 2014 Neurotoxicity refers to the direct or indirect effect of chemicals that disrupt the nervous system of humans or animals. Numerous chemicals can produce neurotoxic diseases in humans, and many more are used as experimental tools to disturb or damage the ...
Brust +15 more
core +2 more sources
Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]
, 2015 Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján +2 more
core +1 more source
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Clinical and Translational Medicine, Volume 8, Issue 1, December 2019., 2019 AbstractPancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor microenvironment contains infiltrating immune cells including cytotoxic T cells; however, there is an overall immunosuppressive milieu.
S. K. Daniel +3 more
wiley +1 more source
Radiosensitizers in cervical cancer. Cisplatin and beyond [PDF]
, 2006 Cervical cancer continues to be a significant health burden worldwide. Globally, the majority of cancers are locally advanced at diagnosis; hence, radiation remains the most frequently used therapeutical modality. Currently, the value of adding cisplatin
Cetina Lucely +3 more
core +2 more sources